News Release

Vitamin D–fortified yoghurt improves cholesterol levels and heart disease biomarkers for diabetics

Peer-Reviewed Publication

BMC (BioMed Central)

People with diabetes are known to have an increased risk of heart disease. New research published in BioMed Central's open access journal BMC Medicine shows that regular consumption of a vitamin D-fortified yoghurt drink improves cholesterol levels and biomarkers of endothelial dysfunction, a precursor of heart disease, in diabetics.

Not having enough vitamin D affects the inner lining of blood vessels (endothelial cells) eventually leading to atherosclerosis and cardiovascular disease. Endothelial dysfunction can be measured by the increased levels of a set of biomarkers, such as serum endothelin-1, E-Selectin and MMP-9. In a double-blind trial, researchers from Tehran investigated the effect of vitamin D on the glycemic status, cholesterol levels and endothelial biomarkers of diabetics. Patients were given either a plain yoghurt drink (Doogh) or the same drink fortified with vitamin D twice a day for 12 weeks.

Researchers from the National Research Institute and Faculty of Nutrition and Food Technology had previously shown that a vitamin D-fortified yoghurt drink could improve the glycemic status of people with type 2 diabetes. In collaboration with Tehran University of Medical Sciences their new trial showed that vitamin D improved the fasting glucose, insulin, QUICK1 (a measure of insulin resistance), and found some improvement in long term HbA1c.

Dr Neyestani explained, "The patients who had taken the vitamin D yoghurt also had improved cholesterol levels with lower total cholesterol and LDL levels and an increase in HDL. All the improvements in cholesterol seemed to be due to the reduction in insulin resistance. The biomarkers of endothelial dysfunction, serum endothelin-1, E-Selectin and MMP-9, levels were also lower for the patients taking vitamin D."

Prof Djazayery continued, "Most of our patients were deficient in vitamin D at the start of the trial but the fortified yoghurt drink elevated most of their levels to normal. However, even amongst those who took the vitamin D supplement, some people (about 5%) remained deficient at the end of the 12 weeks. These people did not show the same improvements. Nevertheless for most diabetics with vitamin D deficiency this is an easy way to improve their outcome."

###

Media Contact
Dr Hilary Glover
Scientific Press Officer, BioMed Central
Tel: 44-20-3192-2370
Email: hilary.glover@biomedcentral.com

Notes to Editors

1. Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: A randomized double-blind clinical trial Sakineh Shab-Bidar, Tirang R Neyestani, Abolghassem Djazayery, Mohammad-Reza Eshraghian, Anahita Houshiarrad, A'azam Gharavi, Ali Kalayi, Nastaran Shariatzadeh, Malihe Zahedirad, Niloufar Khalaji and Homa Haidari BMC Medicine (in press)

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

Article citation and URL available on request at press@biomedcentral.com on the day of publication.

2. BMC Medicine - the flagship medical journal of the BMC series - publishes original research articles, commentaries and reviews in all areas of medical science and clinical practice. To be appropriate for BMC Medicine, articles need to be of outstanding quality, broad interest and special importance. BMC Medicine (ISSN 1741-7015) is indexed/tracked/covered by PubMed, MEDLINE, BIOSIS, CAS, EMBASE, Scopus, Current Contents, Thomson Reuters (ISI) and Google Scholar.

3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.